Journal Mobile Options
Table of Contents
Vol. 36, No. 3, 2009
Issue release date: June 2009
Free Access
Transfus Med Hemother 2009;36:189–198
(DOI:10.1159/000216580)
Review Article · Übersichtsarbeit

Prenatal RhD Testing: A Review of Studies Published from 2006 to 2008

Legler T.J.a · Müller S.P.a · Haverkamp A.a · Grill S.b · Hahn S.b
a Department of Transfusion Medicine, University Medical Center, Göttingen, Germany b University Women’s Hospital, Department Biomedicine, University Clinics, Basel, Switzerland

Abstract

The availability of noninvasive prenatal diagnosis for the fetal RhD status (NIPD RhD) is an obvious benefit for alloimmunized pregnant women. This review gives information about the performance characteristics of current diagnostic technologies and recent promising proof-ofprinciple studies. Notably, during the past 3 years almost twice as much samples have been investigated with NIPD RhD compared with the studies from 1998 to 2005. Thus we have now a lot more information compared with the knowledge before 2006. There is no doubt that funding of the SAFE Network of Excellence (2004–2009) from the European Commission within the framework 6 program has massively increased the worldwide experience in NIPD RhD. In 2009 European funding has been stopped. Because of this large investment from public funding sources, it is now the duty of policy makers (scientific boards, patient groups, physician organizations, and health assurances) to discuss if targetedantenatal Rh prophylaxis should be introduced in German-speaking countries or which additional data are required to make a decision and how these additional studies should be funded.

 goto top of outline Author Contacts

Prof. Dr. med. Tobias J. Legler, Department of Transfusion Medicine, University Medical Center Göttingen, Georg August Universität, 37099 Göttingen, Germany, Tel. +49 551 39-2750, Fax -8691, tlegler@med.uni-goettingen.de


 goto top of outline Article Information

Received: January 21, 2009
Accepted: April 27, 2009
Published online: May 14, 2009
Number of Print Pages : 10


 goto top of outline Publication Details

Transfusion Medicine and Hemotherapy

Vol. 36, No. 3, Year 2009 (Cover Date: June 2009)

Journal Editor: Sibrowski W. (Münster)
ISSN: 1660-3796 (Print), eISSN: 1660-3818 (Online)

For additional information: http://www.karger.com/TMH


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.